Mechanisms, reported research dosage ranges, stability behaviour and storage requirements for the compounds most commonly listed by the suppliers in this directory. Dosage figures are summaries of published literature and widely circulated research protocols — they are not instructions.
BPC-157
Body Protection Compound-157
Pentadecapeptide · gastric-derived
Target mechanism
Upregulates VEGFR2 signalling and nitric-oxide pathways, associated in animal models with angiogenesis and accelerated soft-tissue repair of tendon, ligament and gut lining.
Reported research dosage
Literature and community protocols commonly cite 200–500 mcg per administration, once or twice daily, in cycles of 4–8 weeks.
Stability
Comparatively robust for a peptide; tolerates brief room-temperature excursions during shipping better than most. Half-life: short — minutes to a few hours in circulation.
Storage
Lyophilised: freezer, long-term. Reconstituted: 2–8 °C, use within ~4 weeks, protect from light.
Field note · Human clinical evidence remains limited. Most citations are rodent studies. Often sold as an arginate salt, which is more stable in solution than the acetate form.
TB-500
Thymosin Beta-4 fragment
Synthetic peptide fragment
Target mechanism
Binds G-actin and promotes actin sequestration, implicated in cell migration, endothelial differentiation and wound-site repair.
Reported research dosage
Reported research use is typically 2–2.5 mg twice weekly in a 4–6 week loading phase, then a reduced maintenance frequency.
Stability
Stable as a powder; solution stability is average. Avoid repeated freeze–thaw of reconstituted material. Half-life: long relative to bpc-157 — allows infrequent administration.
Storage
Lyophilised: −20 °C. Reconstituted: refrigerated, ~3–4 weeks.
Field note · Frequently paired with BPC-157 in community protocols. On WADA's prohibited list for competitive athletes.
Clinical titration schedules start at 0.25 mg weekly and escalate over months. Rapid escalation is the single most common cause of adverse gastrointestinal effects.
Stability
Sensitive to heat and agitation. Cold-chain shipping matters; vials that arrive warm should be questioned. Half-life: ≈7 days — weekly administration.
Storage
Lyophilised: refrigerated or frozen. Reconstituted: 2–8 °C, never frozen, discard if cloudy.
Field note · Approved pharmaceutical versions exist. Research-grade vials are not equivalent to a prescription product and carry no dosing assurance — under-dosed batches are a documented problem in this category.
Tirzepatide
GIP / GLP-1 dual agonist
Dual incretin agonist
Target mechanism
Activates both GIP and GLP-1 receptors, producing greater effects on glycaemic control and appetite in trials than GLP-1 agonism alone.
Reported research dosage
Clinical schedules begin at 2.5 mg weekly with escalation at 4-week intervals. Research vials are commonly supplied at 10–60 mg total.
Stability
Similar profile to semaglutide: heat- and shear-sensitive, degrades with shaking. Half-life: ≈5 days — weekly administration.
Storage
Lyophilised: refrigerated/frozen. Reconstituted: 2–8 °C, upright, protect from light.
Field note · The highest-value target for counterfeiting and dilution in the grey market. Independent batch assay is strongly advised before any use.
CJC-1295
Modified GRF (1-29), with or without DAC
Growth hormone releasing hormone analogue
Target mechanism
GHRH analogue that increases the amplitude of endogenous growth hormone pulses. The DAC variant binds albumin, extending duration substantially.
Reported research dosage
No-DAC research protocols cite ~100 mcg per administration, 1–3 times daily; DAC versions are cited at ~1–2 mg weekly.
Stability
Good as powder; moderate in solution. Half-life: no-dac: ~30 minutes · with dac: ~6–8 days.
Storage
Lyophilised: freezer. Reconstituted: 2–8 °C, ~3–4 weeks.
Field note · Commonly combined with a ghrelin mimetic such as Ipamorelin for a synergistic pulse. Confirm which variant you have — DAC and no-DAC are not interchangeable at the same dose.
Ipamorelin
Selective ghrelin receptor agonist
Growth hormone secretagogue
Target mechanism
Selective GHSR-1a agonist that stimulates GH release with minimal impact on cortisol, prolactin or ACTH — the reason it is preferred over older secretagogues.
Reported research dosage
Commonly cited at 100–300 mcg per administration, up to three times daily.
Stability
Stable powder; standard solution handling. Half-life: ≈2 hours.
Field note · Considered the mildest of the secretagogues. Frequently stacked with CJC-1295 no-DAC in reported protocols.
GHK-Cu
Copper tripeptide-1
Copper-binding tripeptide
Target mechanism
Copper complex studied for collagen and elastin synthesis, antioxidant signalling and wound remodelling. Used both topically and, in research contexts, subcutaneously.
Reported research dosage
Topical formulations typically sit at 1–3 mg/mL. Reported subcutaneous research use is far lower, commonly 1–2 mg per administration.
Stability
Distinctive deep blue solution — colour is expected, not contamination. Discolouration toward green or brown suggests degradation. Half-life: short in circulation.
Storage
Lyophilised: cool and dark. Reconstituted: 2–8 °C, protect from light; copper complexes are photosensitive.
Field note · Copper load matters with repeated administration. Topical use has the strongest supporting literature.
Every compound listed is a research chemical without consumer medical approval. This page documents what the literature and market report; it is not medical advice and not a recommendation to use anything described here.